APO Research
Talk to an analyst

APO RESEARCH · REPORT

Statin

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Statin Market Outlook and Growth Opportunities 2026

20 December 2025207 pages

Choose your research edition.

Industry ResearchStatin Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Statin Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Statin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Statin Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Statin Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Statin market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Statin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Statin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Statin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Statin market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Statin market include CHIA TAI TIANQING, Zhejiang Jingxin Pharmaceutical, Shanghai Shyndec Pharmaceutical, Henan Topfond Pharmaceutical, Novartis, Merck, LUNAN BETTER, Livzon Pharmaceutical and Wanbang Biopharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Statin market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Statin and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Statin revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Statin market.

Statin Segment by Company

CHIA TAI TIANQING

Zhejiang Jingxin Pharmaceutical

Shanghai Shyndec Pharmaceutical

Henan Topfond Pharmaceutical

Novartis

Merck

LUNAN BETTER

Livzon Pharmaceutical

Wanbang Biopharmaceuticals

Pfizer

Huizhi

China Resources Double-Crane Pharmaceutical

North China Pharmaceutical

Hanhui Pharmaceutical

Daiichi Sankyo

Beijing Jialin Pharmaceutical

AstraZeneca

Statin Segment by Type

Astrovastatin

Pitavastatin

Rosuvastatin

Others

Statin Segment by Application

Inflammatory Disorders

Cardiovascular Disorders

Obesity

Others

Statin Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Statin status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Statin key companies, revenue, market share, and recent developments.

3. To split the Statin breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Statin market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Statin significant trends, drivers, influence factors in global and regions.

6. To analyze Statin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Statin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Statin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Statin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Statin industry.

Chapter 3: Detailed analysis of Statin company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Statin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Statin in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Statin Industry Trends Table 2. Statin Industry Drivers Table 3. Statin Industry Opportunities and Challenges Table 4. Statin Industry Restraints Table 5. Global Statin Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Statin Revenue Share by Company (2021-2026) Table 7. Global Statin Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Statin Key Company Manufacturing Base & Headquarters Table 9. Global Statin Company, Product Type & Application Table 10. Global Statin Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Statin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Astrovastatin Table 15. Significant Companies of Pitavastatin Table 16. Significant Companies of Rosuvastatin Table 17. Significant Companies of Others Table 18. Global Statin Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Statin Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Statin Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Statin Sales Value Share by Type (2021-2026) Table 22. Global Statin Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Inflammatory Disorders Table 24. Significant Companies of Cardiovascular Disorders Table 25. Significant Companies of Obesity Table 26. Significant Companies of Others Table 27. Global Statin Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Statin Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Statin Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Statin Sales Value Share by Application (2021-2026) Table 31. Global Statin Sales Value Share by Application (2027-2032) Table 32. Global Statin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Statin Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Statin Sales Value Share by Region (2021-2026) Table 35. Global Statin Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Statin Sales Value Share by Region (2027-2032) Table 37. Global Statin Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Statin Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Statin Sales Value Market Share by Country (2021-2026) Table 40. Global Statin Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Statin Sales Value Market Share by Country (2027-2032) Table 42. CHIA TAI TIANQING Company Information Table 43. CHIA TAI TIANQING Business Overview Table 44. CHIA TAI TIANQING Statin Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. CHIA TAI TIANQING Statin Product Portfolio Table 46. CHIA TAI TIANQING Recent Development Table 47. Zhejiang Jingxin Pharmaceutical Company Information Table 48. Zhejiang Jingxin Pharmaceutical Business Overview Table 49. Zhejiang Jingxin Pharmaceutical Statin Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Zhejiang Jingxin Pharmaceutical Statin Product Portfolio Table 51. Zhejiang Jingxin Pharmaceutical Recent Development Table 52. Shanghai Shyndec Pharmaceutical Company Information Table 53. Shanghai Shyndec Pharmaceutical Business Overview Table 54. Shanghai Shyndec Pharmaceutical Statin Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Shanghai Shyndec Pharmaceutical Statin Product Portfolio Table 56. Shanghai Shyndec Pharmaceutical Recent Development Table 57. Henan Topfond Pharmaceutical Company Information Table 58. Henan Topfond Pharmaceutical Business Overview Table 59. Henan Topfond Pharmaceutical Statin Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Henan Topfond Pharmaceutical Statin Product Portfolio Table 61. Henan Topfond Pharmaceutical Recent Development Table 62. Novartis Company Information Table 63. Novartis Business Overview Table 64. Novartis Statin Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Novartis Statin Product Portfolio Table 66. Novartis Recent Development Table 67. Merck Company Information Table 68. Merck Business Overview Table 69. Merck Statin Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Merck Statin Product Portfolio Table 71. Merck Recent Development Table 72. LUNAN BETTER Company Information Table 73. LUNAN BETTER Business Overview Table 74. LUNAN BETTER Statin Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. LUNAN BETTER Statin Product Portfolio Table 76. LUNAN BETTER Recent Development Table 77. Livzon Pharmaceutical Company Information Table 78. Livzon Pharmaceutical Business Overview Table 79. Livzon Pharmaceutical Statin Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Livzon Pharmaceutical Statin Product Portfolio Table 81. Livzon Pharmaceutical Recent Development Table 82. Wanbang Biopharmaceuticals Company Information Table 83. Wanbang Biopharmaceuticals Business Overview Table 84. Wanbang Biopharmaceuticals Statin Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Wanbang Biopharmaceuticals Statin Product Portfolio Table 86. Wanbang Biopharmaceuticals Recent Development Table 87. Pfizer Company Information Table 88. Pfizer Business Overview Table 89. Pfizer Statin Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Pfizer Statin Product Portfolio Table 91. Pfizer Recent Development Table 92. Huizhi Company Information Table 93. Huizhi Business Overview Table 94. Huizhi Statin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Huizhi Statin Product Portfolio Table 96. Huizhi Recent Development Table 97. China Resources Double-Crane Pharmaceutical Company Information Table 98. China Resources Double-Crane Pharmaceutical Business Overview Table 99. China Resources Double-Crane Pharmaceutical Statin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. China Resources Double-Crane Pharmaceutical Statin Product Portfolio Table 101. China Resources Double-Crane Pharmaceutical Recent Development Table 102. North China Pharmaceutical Company Information Table 103. North China Pharmaceutical Business Overview Table 104. North China Pharmaceutical Statin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. North China Pharmaceutical Statin Product Portfolio Table 106. North China Pharmaceutical Recent Development Table 107. Hanhui Pharmaceutical Company Information Table 108. Hanhui Pharmaceutical Business Overview Table 109. Hanhui Pharmaceutical Statin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Hanhui Pharmaceutical Statin Product Portfolio Table 111. Hanhui Pharmaceutical Recent Development Table 112. Daiichi Sankyo Company Information Table 113. Daiichi Sankyo Business Overview Table 114. Daiichi Sankyo Statin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Daiichi Sankyo Statin Product Portfolio Table 116. Daiichi Sankyo Recent Development Table 117. Beijing Jialin Pharmaceutical Company Information Table 118. Beijing Jialin Pharmaceutical Business Overview Table 119. Beijing Jialin Pharmaceutical Statin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Beijing Jialin Pharmaceutical Statin Product Portfolio Table 121. Beijing Jialin Pharmaceutical Recent Development Table 122. AstraZeneca Company Information Table 123. AstraZeneca Business Overview Table 124. AstraZeneca Statin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. AstraZeneca Statin Product Portfolio Table 126. AstraZeneca Recent Development Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. Statin Product Image Figure 2. Global Statin Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Statin Market Size (2021-2032) & (US$ Million) Figure 4. Global Statin Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Astrovastatin Image Figure 8. Pitavastatin Image Figure 9. Rosuvastatin Image Figure 10. Others Image Figure 11. Global Statin Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Statin Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Statin Sales Value Share by Type (2021-2032) Figure 14. Inflammatory Disorders Image Figure 15. Cardiovascular Disorders Image Figure 16. Obesity Image Figure 17. Others Image Figure 18. Global Statin Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Statin Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Statin Sales Value Share by Application (2021-2032) Figure 21. Global Statin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Statin Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Statin Sales Value (2021-2032) & (US$ Million) Figure 24. North America Statin Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Statin Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Statin Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Statin Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Statin Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Statin Sales Value (2021-2032) & (US$ Million) Figure 30. South America Statin Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Statin Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Statin Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Statin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Statin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Statin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Astrovastatin
  • Pitavastatin
  • Rosuvastatin
  • Others
Applications
  • Inflammatory Disorders
  • Cardiovascular Disorders
  • Obesity
  • Others
Companies covered
  • CHIA TAI TIANQING
  • Zhejiang Jingxin Pharmaceutical
  • Shanghai Shyndec Pharmaceutical
  • Henan Topfond Pharmaceutical
  • Novartis
  • Merck
  • LUNAN BETTER
  • Livzon Pharmaceutical
  • Wanbang Biopharmaceuticals
  • Pfizer
  • Huizhi
  • China Resources Double-Crane Pharmaceutical
  • North China Pharmaceutical
  • Hanhui Pharmaceutical
  • Daiichi Sankyo
  • Beijing Jialin Pharmaceutical
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Statin Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Statin Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Statin Market Dynamics
  1. 2.1 Statin Industry Trends
  2. 2.2 Statin Industry Drivers
  3. 2.3 Statin Industry Opportunities and Challenges
  4. 2.4 Statin Industry Restraints
3 Statin Market by Company
  1. 3.1 Global Statin Company Revenue Ranking in 2025
  2. 3.2 Global Statin Revenue by Company (2021-2026)
  3. 3.3 Global Statin Company Ranking (2024-2026)
  4. 3.4 Global Statin Company Manufacturing Base and Headquarters
  5. 3.5 Global Statin Company Product Type and Application
  6. 3.6 Global Statin Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Statin Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Statin Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Statin Market by Type
  1. 4.1 Statin Type Introduction
  2. 4.1.1 Astrovastatin
  3. 4.1.2 Pitavastatin
  4. 4.1.3 Rosuvastatin
  5. 4.1.4 Others
  6. 4.2 Global Statin Sales Value by Type
  7. 4.2.1 Global Statin Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Statin Sales Value by Type (2021-2032)
  9. 4.2.3 Global Statin Sales Value Share by Type (2021-2032)
5 Statin Market by Application
  1. 5.1 Statin Application Introduction
  2. 5.1.1 Inflammatory Disorders
  3. 5.1.2 Cardiovascular Disorders
  4. 5.1.3 Obesity
  5. 5.1.4 Others
  6. 5.2 Global Statin Sales Value by Application
  7. 5.2.1 Global Statin Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Statin Sales Value by Application (2021-2032)
  9. 5.2.3 Global Statin Sales Value Share by Application (2021-2032)
6 Statin Regional Value Analysis
  1. 6.1 Global Statin Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Statin Sales Value by Region (2021-2032)
  3. 6.2.1 Global Statin Sales Value by Region: 2021-2026
  4. 6.2.2 Global Statin Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Statin Sales Value (2021-2032)
  7. 6.3.2 North America Statin Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Statin Sales Value (2021-2032)
  10. 6.4.2 Europe Statin Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Statin Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Statin Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Statin Sales Value (2021-2032)
  16. 6.6.2 South America Statin Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Statin Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Statin Sales Value Share by Country, 2025 VS 2032
7 Statin Country-level Value Analysis
  1. 7.1 Global Statin Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Statin Sales Value by Country (2021-2032)
  3. 7.2.1 Global Statin Sales Value by Country (2021-2026)
  4. 7.2.2 Global Statin Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Statin Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Statin Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Statin Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Statin Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Statin Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Statin Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Statin Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Statin Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Statin Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Statin Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Statin Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Statin Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Statin Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Statin Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Statin Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Statin Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Statin Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Statin Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Statin Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Statin Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Statin Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Statin Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Statin Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Statin Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Statin Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Statin Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Statin Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Statin Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Statin Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Statin Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Statin Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Statin Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Statin Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Statin Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Statin Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Statin Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Statin Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Statin Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Statin Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Statin Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Statin Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Statin Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Statin Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Statin Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Statin Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Statin Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Statin Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Statin Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Statin Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Statin Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Statin Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Statin Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Statin Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Statin Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Statin Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Statin Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Statin Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Statin Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Statin Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Statin Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Statin Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Statin Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Statin Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Statin Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Statin Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Statin Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Statin Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Statin Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Statin Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Statin Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Statin Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Statin Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Statin Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Statin Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Statin Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Statin Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Statin Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Statin Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Statin Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Statin Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Statin Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Statin Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Statin Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Statin Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CHIA TAI TIANQING
  2. 8.1.1 CHIA TAI TIANQING Company Information
  3. 8.1.2 CHIA TAI TIANQING Business Overview
  4. 8.1.3 CHIA TAI TIANQING Statin Revenue and Gross Margin (2021-2026)
  5. 8.1.4 CHIA TAI TIANQING Statin Product Portfolio
  6. 8.1.5 CHIA TAI TIANQING Recent Developments
  7. 8.2 Zhejiang Jingxin Pharmaceutical
  8. 8.2.1 Zhejiang Jingxin Pharmaceutical Company Information
  9. 8.2.2 Zhejiang Jingxin Pharmaceutical Business Overview
  10. 8.2.3 Zhejiang Jingxin Pharmaceutical Statin Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Zhejiang Jingxin Pharmaceutical Statin Product Portfolio
  12. 8.2.5 Zhejiang Jingxin Pharmaceutical Recent Developments
  13. 8.3 Shanghai Shyndec Pharmaceutical
  14. 8.3.1 Shanghai Shyndec Pharmaceutical Company Information
  15. 8.3.2 Shanghai Shyndec Pharmaceutical Business Overview
  16. 8.3.3 Shanghai Shyndec Pharmaceutical Statin Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai Shyndec Pharmaceutical Statin Product Portfolio
  18. 8.3.5 Shanghai Shyndec Pharmaceutical Recent Developments
  19. 8.4 Henan Topfond Pharmaceutical
  20. 8.4.1 Henan Topfond Pharmaceutical Company Information
  21. 8.4.2 Henan Topfond Pharmaceutical Business Overview
  22. 8.4.3 Henan Topfond Pharmaceutical Statin Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Henan Topfond Pharmaceutical Statin Product Portfolio
  24. 8.4.5 Henan Topfond Pharmaceutical Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Statin Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Statin Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Merck
  32. 8.6.1 Merck Company Information
  33. 8.6.2 Merck Business Overview
  34. 8.6.3 Merck Statin Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck Statin Product Portfolio
  36. 8.6.5 Merck Recent Developments
  37. 8.7 LUNAN BETTER
  38. 8.7.1 LUNAN BETTER Company Information
  39. 8.7.2 LUNAN BETTER Business Overview
  40. 8.7.3 LUNAN BETTER Statin Revenue and Gross Margin (2021-2026)
  41. 8.7.4 LUNAN BETTER Statin Product Portfolio
  42. 8.7.5 LUNAN BETTER Recent Developments
  43. 8.8 Livzon Pharmaceutical
  44. 8.8.1 Livzon Pharmaceutical Company Information
  45. 8.8.2 Livzon Pharmaceutical Business Overview
  46. 8.8.3 Livzon Pharmaceutical Statin Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Livzon Pharmaceutical Statin Product Portfolio
  48. 8.8.5 Livzon Pharmaceutical Recent Developments
  49. 8.9 Wanbang Biopharmaceuticals
  50. 8.9.1 Wanbang Biopharmaceuticals Company Information
  51. 8.9.2 Wanbang Biopharmaceuticals Business Overview
  52. 8.9.3 Wanbang Biopharmaceuticals Statin Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Wanbang Biopharmaceuticals Statin Product Portfolio
  54. 8.9.5 Wanbang Biopharmaceuticals Recent Developments
  55. 8.10 Pfizer
  56. 8.10.1 Pfizer Company Information
  57. 8.10.2 Pfizer Business Overview
  58. 8.10.3 Pfizer Statin Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Pfizer Statin Product Portfolio
  60. 8.10.5 Pfizer Recent Developments
  61. 8.11 Huizhi
  62. 8.11.1 Huizhi Company Information
  63. 8.11.2 Huizhi Business Overview
  64. 8.11.3 Huizhi Statin Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Huizhi Statin Product Portfolio
  66. 8.11.5 Huizhi Recent Developments
  67. 8.12 China Resources Double-Crane Pharmaceutical
  68. 8.12.1 China Resources Double-Crane Pharmaceutical Company Information
  69. 8.12.2 China Resources Double-Crane Pharmaceutical Business Overview
  70. 8.12.3 China Resources Double-Crane Pharmaceutical Statin Revenue and Gross Margin (2021-2026)
  71. 8.12.4 China Resources Double-Crane Pharmaceutical Statin Product Portfolio
  72. 8.12.5 China Resources Double-Crane Pharmaceutical Recent Developments
  73. 8.13 North China Pharmaceutical
  74. 8.13.1 North China Pharmaceutical Company Information
  75. 8.13.2 North China Pharmaceutical Business Overview
  76. 8.13.3 North China Pharmaceutical Statin Revenue and Gross Margin (2021-2026)
  77. 8.13.4 North China Pharmaceutical Statin Product Portfolio
  78. 8.13.5 North China Pharmaceutical Recent Developments
  79. 8.14 Hanhui Pharmaceutical
  80. 8.14.1 Hanhui Pharmaceutical Company Information
  81. 8.14.2 Hanhui Pharmaceutical Business Overview
  82. 8.14.3 Hanhui Pharmaceutical Statin Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Hanhui Pharmaceutical Statin Product Portfolio
  84. 8.14.5 Hanhui Pharmaceutical Recent Developments
  85. 8.15 Daiichi Sankyo
  86. 8.15.1 Daiichi Sankyo Company Information
  87. 8.15.2 Daiichi Sankyo Business Overview
  88. 8.15.3 Daiichi Sankyo Statin Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Daiichi Sankyo Statin Product Portfolio
  90. 8.15.5 Daiichi Sankyo Recent Developments
  91. 8.16 Beijing Jialin Pharmaceutical
  92. 8.16.1 Beijing Jialin Pharmaceutical Company Information
  93. 8.16.2 Beijing Jialin Pharmaceutical Business Overview
  94. 8.16.3 Beijing Jialin Pharmaceutical Statin Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Beijing Jialin Pharmaceutical Statin Product Portfolio
  96. 8.16.5 Beijing Jialin Pharmaceutical Recent Developments
  97. 8.17 AstraZeneca
  98. 8.17.1 AstraZeneca Company Information
  99. 8.17.2 AstraZeneca Business Overview
  100. 8.17.3 AstraZeneca Statin Revenue and Gross Margin (2021-2026)
  101. 8.17.4 AstraZeneca Statin Product Portfolio
  102. 8.17.5 AstraZeneca Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst